The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Nucleic Vaccine Market Research Report 2024
Synopsis
A nucleic vaccine is to directly introduce an exogenous gene (DNA or RNA) encoding an antigen protein into an animal body cell, and synthesize the antigen protein through an expression system of a host cell to induce the host to produce an immune response to the antigen protein to achieve prevention And the purpose of treating the disease.
The global Nucleic Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Nucleic Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Vaccine.
Report Scope
The Nucleic Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nucleic Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Moderna
CureVac
Inovio
Sanofi
GSK
CNBG
Hualan Bio
Zhifei Shengwu
Liaoning Chengda
BioKangtai
CanSinoBIO
Walvax Biotechnology
Fosun Pharma
Segment by Type
Preventive Nucleic Vaccine
Therapeutic Nucleic Vaccine
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nucleic Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nucleic Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A nucleic vaccine is to directly introduce an exogenous gene (DNA or RNA) encoding an antigen protein into an animal body cell, and synthesize the antigen protein through an expression system of a host cell to induce the host to produce an immune response to the antigen protein to achieve prevention And the purpose of treating the disease.
The global Nucleic Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Nucleic Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Vaccine.
Report Scope
The Nucleic Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nucleic Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Moderna
CureVac
Inovio
Sanofi
GSK
CNBG
Hualan Bio
Zhifei Shengwu
Liaoning Chengda
BioKangtai
CanSinoBIO
Walvax Biotechnology
Fosun Pharma
Segment by Type
Preventive Nucleic Vaccine
Therapeutic Nucleic Vaccine
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nucleic Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nucleic Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Nucleic Vaccine Market Overview
1.1 Product Overview and Scope of Nucleic Vaccine
1.2 Nucleic Vaccine Segment by Type
1.2.1 Global Nucleic Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Preventive Nucleic Vaccine
1.2.3 Therapeutic Nucleic Vaccine
1.3 Nucleic Vaccine Segment by Application
1.3.1 Global Nucleic Vaccine Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Nucleic Vaccine Market Size Estimates and Forecasts
1.4.1 Global Nucleic Vaccine Revenue 2019-2030
1.4.2 Global Nucleic Vaccine Sales 2019-2030
1.4.3 Global Nucleic Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Nucleic Vaccine Market Competition by Manufacturers
2.1 Global Nucleic Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Nucleic Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Nucleic Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Nucleic Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nucleic Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nucleic Vaccine, Product Type & Application
2.7 Nucleic Vaccine Market Competitive Situation and Trends
2.7.1 Nucleic Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Nucleic Vaccine Players Market Share by Revenue
2.7.3 Global Nucleic Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Nucleic Vaccine Retrospective Market Scenario by Region
3.1 Global Nucleic Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Nucleic Vaccine Global Nucleic Vaccine Sales by Region: 2019-2030
3.2.1 Global Nucleic Vaccine Sales by Region: 2019-2024
3.2.2 Global Nucleic Vaccine Sales by Region: 2025-2030
3.3 Global Nucleic Vaccine Global Nucleic Vaccine Revenue by Region: 2019-2030
3.3.1 Global Nucleic Vaccine Revenue by Region: 2019-2024
3.3.2 Global Nucleic Vaccine Revenue by Region: 2025-2030
3.4 North America Nucleic Vaccine Market Facts & Figures by Country
3.4.1 North America Nucleic Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Nucleic Vaccine Sales by Country (2019-2030)
3.4.3 North America Nucleic Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Nucleic Vaccine Market Facts & Figures by Country
3.5.1 Europe Nucleic Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Nucleic Vaccine Sales by Country (2019-2030)
3.5.3 Europe Nucleic Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nucleic Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Nucleic Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Nucleic Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Nucleic Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Nucleic Vaccine Market Facts & Figures by Country
3.7.1 Latin America Nucleic Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Nucleic Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Nucleic Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Nucleic Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Nucleic Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Nucleic Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Nucleic Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nucleic Vaccine Sales by Type (2019-2030)
4.1.1 Global Nucleic Vaccine Sales by Type (2019-2024)
4.1.2 Global Nucleic Vaccine Sales by Type (2025-2030)
4.1.3 Global Nucleic Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Nucleic Vaccine Revenue by Type (2019-2030)
4.2.1 Global Nucleic Vaccine Revenue by Type (2019-2024)
4.2.2 Global Nucleic Vaccine Revenue by Type (2025-2030)
4.2.3 Global Nucleic Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Nucleic Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Nucleic Vaccine Sales by Application (2019-2030)
5.1.1 Global Nucleic Vaccine Sales by Application (2019-2024)
5.1.2 Global Nucleic Vaccine Sales by Application (2025-2030)
5.1.3 Global Nucleic Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Nucleic Vaccine Revenue by Application (2019-2030)
5.2.1 Global Nucleic Vaccine Revenue by Application (2019-2024)
5.2.2 Global Nucleic Vaccine Revenue by Application (2025-2030)
5.2.3 Global Nucleic Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Nucleic Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Moderna
6.1.1 Moderna Corporation Information
6.1.2 Moderna Description and Business Overview
6.1.3 Moderna Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Moderna Nucleic Vaccine Product Portfolio
6.1.5 Moderna Recent Developments/Updates
6.2 CureVac
6.2.1 CureVac Corporation Information
6.2.2 CureVac Description and Business Overview
6.2.3 CureVac Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CureVac Nucleic Vaccine Product Portfolio
6.2.5 CureVac Recent Developments/Updates
6.3 Inovio
6.3.1 Inovio Corporation Information
6.3.2 Inovio Description and Business Overview
6.3.3 Inovio Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Inovio Nucleic Vaccine Product Portfolio
6.3.5 Inovio Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Nucleic Vaccine Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 GSK
6.5.1 GSK Corporation Information
6.5.2 GSK Description and Business Overview
6.5.3 GSK Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GSK Nucleic Vaccine Product Portfolio
6.5.5 GSK Recent Developments/Updates
6.6 CNBG
6.6.1 CNBG Corporation Information
6.6.2 CNBG Description and Business Overview
6.6.3 CNBG Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 CNBG Nucleic Vaccine Product Portfolio
6.6.5 CNBG Recent Developments/Updates
6.7 Hualan Bio
6.6.1 Hualan Bio Corporation Information
6.6.2 Hualan Bio Description and Business Overview
6.6.3 Hualan Bio Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hualan Bio Nucleic Vaccine Product Portfolio
6.7.5 Hualan Bio Recent Developments/Updates
6.8 Zhifei Shengwu
6.8.1 Zhifei Shengwu Corporation Information
6.8.2 Zhifei Shengwu Description and Business Overview
6.8.3 Zhifei Shengwu Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Zhifei Shengwu Nucleic Vaccine Product Portfolio
6.8.5 Zhifei Shengwu Recent Developments/Updates
6.9 Liaoning Chengda
6.9.1 Liaoning Chengda Corporation Information
6.9.2 Liaoning Chengda Description and Business Overview
6.9.3 Liaoning Chengda Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Liaoning Chengda Nucleic Vaccine Product Portfolio
6.9.5 Liaoning Chengda Recent Developments/Updates
6.10 BioKangtai
6.10.1 BioKangtai Corporation Information
6.10.2 BioKangtai Description and Business Overview
6.10.3 BioKangtai Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 BioKangtai Nucleic Vaccine Product Portfolio
6.10.5 BioKangtai Recent Developments/Updates
6.11 CanSinoBIO
6.11.1 CanSinoBIO Corporation Information
6.11.2 CanSinoBIO Nucleic Vaccine Description and Business Overview
6.11.3 CanSinoBIO Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 CanSinoBIO Nucleic Vaccine Product Portfolio
6.11.5 CanSinoBIO Recent Developments/Updates
6.12 Walvax Biotechnology
6.12.1 Walvax Biotechnology Corporation Information
6.12.2 Walvax Biotechnology Nucleic Vaccine Description and Business Overview
6.12.3 Walvax Biotechnology Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Walvax Biotechnology Nucleic Vaccine Product Portfolio
6.12.5 Walvax Biotechnology Recent Developments/Updates
6.13 Fosun Pharma
6.13.1 Fosun Pharma Corporation Information
6.13.2 Fosun Pharma Nucleic Vaccine Description and Business Overview
6.13.3 Fosun Pharma Nucleic Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Fosun Pharma Nucleic Vaccine Product Portfolio
6.13.5 Fosun Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nucleic Vaccine Industry Chain Analysis
7.2 Nucleic Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nucleic Vaccine Production Mode & Process
7.4 Nucleic Vaccine Sales and Marketing
7.4.1 Nucleic Vaccine Sales Channels
7.4.2 Nucleic Vaccine Distributors
7.5 Nucleic Vaccine Customers
8 Nucleic Vaccine Market Dynamics
8.1 Nucleic Vaccine Industry Trends
8.2 Nucleic Vaccine Market Drivers
8.3 Nucleic Vaccine Market Challenges
8.4 Nucleic Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
